WeLeader Biomedical Co

WeLeader Biomedical Co Net Debt per Share

The Net Debt per Share of WeLeader Biomedical Co (7713.TWO) as of Oct 23, 2026 is 10.74 TWD. In the previous year, Net Debt per Share was 8.75 TWD — a change of 22.73% (higher).

Net Debt per Share

10.74TWD

YoY

22.73%

Last updated:

Net Debt per Share of WeLeader Biomedical Co is 2025 10.74 TWD. Net Debt per Share of WeLeader Biomedical Co was 2024 8.75 TWD. It decreases by 22.73% higher compared to the previous year.

The WeLeader Biomedical Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2020
7.16 TWD
Jan 1, 2021
0.41 TWD
Jan 1, 2022
5.94 TWD
Jan 1, 2023
5.48 TWD
Jan 1, 2024
8.75 TWD
Jan 1, 2025
10.74 TWD
The WeLeader Biomedical Co Net Debt per Share history
YEARNet Debt per ShareYoY
10.74TWD+22.73%
8.75TWD+59.81%
5.48TWD-7.85%
5.94TWD+1,348.65%
0.41TWD-94.27%
7.16TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Net Debt per Share of WeLeader Biomedical Co is 10.74 TWD in 2025.

Net Debt per Share of WeLeader Biomedical Co changed from 8.75 TWD to 10.74 TWD, representing a 22.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co